RxDoctor Payments Data

Tyler Christensen, MD

Urology · Ogden, UTNPI 1811097629

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.1% of the total across 502 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 53 manufacturers reported payments, led by Boston Scientific at 32.9% of the total.

$11,516in general payments, 2019–2025

Across 502 payments — averaging $22.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • Astellas Pharma US Inc$1K
  • AbbVie$818
  • Pfizer$587
  • Dendreon Pharmaceuticals LLC$535
  • Johnson & Johnson$402
  • plus $4K from 47 others

What the payments were for

  • Food & beverage$11,06496%
  • Education$4524%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,516 in reported general payments places this provider in the 80th percentile of 96 urology providers in Utah.

See all urology providers in Utah

Medicare billing

Part B allowed, 2024
$402,175
Medicare patients
417
Services billed
4,860

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide99$1,372,363
OrgovyxRelugolix103$262,742
MyrbetriqMirabegron77$52,119
Abiraterone Acetate25$36,897
Trospium Chloride42$4,101
Tamsulosin Hcl290$3,443
Cephalexin105$2,157
Gentamicin Sulfate19$1,816
Finasteride156$1,493
Methenamine Hippurate12$1,443
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim50$519
Ciprofloxacin Hcl67$297
Prednisone27$249
Oxybutynin Chloride ErOxybutynin Chloride11$99
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen16$64

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,237$1,424,482176 claims
Sumitomo Pharma America, Inc.Orgovyx$295$262,742103 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$16$36,89725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 96 urology providers in Utah.

Other urology in Ogden

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →